2. Antibody-drug Conjugate/ADC Related Anti-infection
  3. Antibody-Drug Conjugates (ADCs) Bacterial
  4. Indatuximab ravtansine

Indatuximab ravtansine  (Synonyms: BT-062; nBT062-DM4)

Cat. No.: HY-141607

Molarity Calculator

Indatuximab ravtansine (BT-062) is an antibody-drug conjugate (ADC) (Antibody-Drug Conjugates (ADCs)) based on a murine/human chimeric form of B-B4 (specific for CD138), linked to the maytansinoid agent DM4 by disulphide bonds. Indatuximab ravtansine shows anti-tumor activities.

For research use only. We do not sell to patients.

Indatuximab ravtansine Chemical Structure

Indatuximab ravtansine Chemical Structure

CAS No. : 1238517-16-2

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Indatuximab ravtansine Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Indatuximab ravtansine (BT-062) is an antibody-drug conjugate (ADC) (Antibody-Drug Conjugates (ADCs)) based on a murine/human chimeric form of B-B4 (specific for CD138), linked to the maytansinoid agent DM4 by disulphide bonds. Indatuximab ravtansine shows anti-tumor activities[1].

In Vitro

Indatuximab ravtansine (1 pM-100 nM; 5 days) shows cytotoxic effects in RPMI 8226, MOLP-8 and U266 cell lines (significant CD138 expression), with IC50 values of 200 pM, 40 pM, and 20 pM for RPMI 8226, MOLP-8, and U266 cells, respectively[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Indatuximab ravtansine Related Antibodies

Cell Viability Assay[1]

Cell Line: RPMI 8226, MOLP-8 and U266 cell lines
Concentration: 1 pM-100 nM
Incubation Time: 5 days
Result: Showed cytotoxic effects in RPMI 8226, MOLP-8 and U266 cell lines.
In Vivo

Indatuximab ravtansine (5.3-21.2 mg/kg; i.v.; once) inhibits multiple myeloma tumour growth in vivo and improves host survival[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: SCID mice inoculated with MOLP-8 multiple myeloma xenografts[1]
Dosage: 5.3 mg/kg, 10.6 mg/kg or 21.2 mg/kg
Administration: i.v.; once
Result: Inhibited multiple myeloma tumour growth in vivo and improved host survival.
CAS No.
SMILES

[Indatuximab ravtansine]
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Indatuximab ravtansine Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Indatuximab ravtansine1238517-16-2BT-062 nBT062-DM4BT062BT 062Antibody-Drug Conjugates (ADCs)BacterialAntibody-Drug ConjugatesCD138ADCanti-tumor activitiesInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Indatuximab ravtansine
Cat. No.:
HY-141607
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (0 KB) Français - FR (0 KB) Deutsch - DE (0 KB) Norwegian - NO (0 KB) Español - ES (0 KB) Swedish - SV (0 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.